Crossmark

Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?

Crossref DOI link: https://doi.org/10.1186/s40959-018-0031-4

Published Online: 2018-06-15

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pettit, Syril D. https://orcid.org/0000-0002-4320-5343
Kirch, Rebecca
License Information

Text and Data Mining valid from 2018-06-15
More Information

Article History

Received: 28 March 2018

Accepted: 30 May 2018

First Online: 15 June 2018

Ethics approval and consent to participate

: No novel human or animal studies were conducted for this paper thus ethical statements in this regard are not applicable to this paper – all information included here is from previously published and publicly accessible sources. Consent to participate is not applicable.

: The authors offer consent for publication of this manuscript.

: Syril Pettit and Rebecca Kirch declare they have no competing interests. In addition to her role as a student at the UNC Gillings School of Global Public Health, Syril Pettit is also an employee of the non-profit Health and Environmental Sciences Institute (HESI). This work was not conducted as a term of her employment at HESI and she received no funding support from HESI. No conflicts are declared.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.